Plimoth Trust Co. LLC Has $5.87 Million Stake in Johnson & Johnson (NYSE:JNJ)

Plimoth Trust Co. LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 0.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 35,379 shares of the company’s stock after purchasing an additional 71 shares during the quarter. Johnson & Johnson comprises approximately 1.5% of Plimoth Trust Co. LLC’s investment portfolio, making the stock its 12th largest holding. Plimoth Trust Co. LLC’s holdings in Johnson & Johnson were worth $5,867,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock worth $33,666,460,000 after acquiring an additional 1,772,706 shares in the last quarter. Geode Capital Management LLC boosted its stake in Johnson & Johnson by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company’s stock valued at $8,321,881,000 after purchasing an additional 1,561,036 shares during the last quarter. Northern Trust Corp increased its holdings in Johnson & Johnson by 12.3% during the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares in the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $4,390,037,000. Finally, Wellington Management Group LLP lifted its holdings in shares of Johnson & Johnson by 1.8% in the fourth quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company’s stock valued at $3,522,447,000 after purchasing an additional 431,205 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 1.1%

JNJ stock opened at $150.77 on Friday. The stock has a fifty day moving average of $154.11 and a 200-day moving average of $153.64. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a market capitalization of $362.76 billion, a price-to-earnings ratio of 16.77, a PEG ratio of 2.28 and a beta of 0.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.45%. Johnson & Johnson’s payout ratio is presently 57.84%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on JNJ shares. Morgan Stanley increased their price target on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 16th. Raymond James Financial lowered their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a report on Monday, April 14th. Royal Bank Of Canada restated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, June 5th. Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.